Contraceptives Market Report 2025

The contraceptives market size has grown strongly in recent years. It will grow from $27.92 billion in 2024 to $30.05 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to introduction ofThe birth control pill, increased awareness and education about contraception, legal and social changes promoting reproductive rights, global population control initiatives, increase inThe use of generic and low-cost drugs and devices.

The contraceptives market size is expected to see strong growth in the next few years. It will grow to $40.89 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growing focus on male contraceptives, increased access to contraception in developing countries, integration of digital health technologies in contraception, rising demand for long-acting reversible contraceptives (LARCS), growing accessibility to over-the-counter drugs on the online platform. Major trends in the forecast period include technological advancements in contraceptive methods, shift towards non-hormonal and natural contraceptive methods, expansion of over-the-counter access to certain contraceptives, emphasis on user-friendly and discreet contraceptive options, integration of telemedicine in contraceptive counseling and prescriptions.

The rising frequency of sexually transmitted illnesses or diseases is driving the demand for contraceptives. Sexually transmitted diseases (STDs) are infections spread from one person to another through sexual interaction. The most typical contact occurs during anal, oral, and vaginal intercourse and they can spread through other close physical contact methods. Contraceptives are employed to manage the transmission of sexually transmitted diseases like herpes and HPV, primarily through skin-to-skin contact. For instance, in May 2023, according to the Minnesota Department of Health, a US-based state health agency of the State of Minnesota, primary and secondary syphilis cases climbed 19% in 2022, from 564 in 2021 to 676 in 2022. In 2022, 20 instances of congenital syphilis in babies were recorded. This represents a 42 % rise from 2021 when 14 cases of congenital syphilis were documented. Therefore, the increase in sexually transmitted illnesses or diseases is expected to boost the demand for contraceptives during the forecast period.

The global rise in population rates is expected to propel the growth of the contraceptive market in the coming years. Population refers to the overall number of individuals, species, or people living in a certain geographic region, country, or the entire planet. Contraceptives play a significant part in decreasing population by allowing couples and individuals to regulate and plan their household size and child spacing. For instance, in December 2022, according to the United Nations Conference on Trade and Development, a Switzerland-based intergovernmental body inside the United Nations Secretariat that promotes developing nations' interests in global commerce, the global population is expected to have increased by 0. 9% in 2021 and to exceed 8 billion by 2022. Therefore, the global rise in population rates is driving the contraceptive market.

Major companies in the contraceptives market are concentrating on developing innovative products such as Single Rod Subdermal Implants and Subcutaneous Injectable Contraceptives to improve user convenience, boost effectiveness, and provide long-term birth control solutions. These advancements aim to minimize the need for frequent dosing, enhance accessibility, and reduce side effects, offering more reliable and discreet contraceptive options for individuals seeking improved reproductive health management. For example, in October 2023, India's Health and Family Welfare Ministry introduced two new methods - the Single Rod Subdermal Implant and Subcutaneous Injectable Contraceptive - under the National Family Planning Programme to enhance family planning services. These methods are designed to improve maternal and infant health outcomes by offering more family planning options. The introduction of these contraceptives aims to lower maternal and infant morbidity and mortality rates. This initiative is part of a larger effort to improve reproductive health services in Karnataka, ensuring that women have access to safe and effective contraceptive methods.

Major companies operating in the contraceptives market are focusing on innovative products, such as Opill, progestin-only daily oral contraceptives, to better meet the needs of their existing consumers. Opill progestin-only daily oral contraceptives, often known as the mini-pill, are a kind of birth control pill that includes just progestin, a synthetic version of the hormone progesterone. For instance, in July 2023, Perrigo Company plc, an Ireland-based manufacturing company of over-the-counter pharmaceuticals, announced U. S. Food and Drug Administration (FDA) approval for Opill progestin-only daily oral contraceptives. Opill is the very first birth control pill available without a prescription in the United States. Opill can significantly improve women's availability of contraceptives and is a genuine testament to Perrigo's constant dedication to delivering meaningful solutions that improve people's lives.

In March 2024, Insud Pharma, a Spain-based pharmaceutical manufacturer, acquired oral and injectable contraceptives from Viatris for an undisclosed amount. This acquisition allows Insud Pharma to strengthen its women's health product portfolio by incorporating Viatris' contraceptive offerings, expanding its market presence, and providing a wider range of reproductive healthcare solutions to meet the increasing demand for contraceptive options. Viatris, a US-based pharmaceutical company, specializes in the manufacturing of pharmaceuticals.

Major companies operating in the contraceptives market include Merck & Co. Inc., Bayer AG, Church & Dwight Co. Inc., Cipla Inc., Reckitt Benckiser Group plc, Agile Therapeutics Inc., Allergan Ltd., Aurobindo Pharma Limited, Famy Care Ltd., Glenmark Pharmaceuticals Limited, HLL Lifecare Limited, Johnson & Johnson, Laboratoire HRA Pharma SAS, Lupin Limited, Mankind Pharma Ltd., Mayer Laboratories Inc., Medisafe Distribution Inc., Mithra Pharmaceuticals SA, Mylan NV, Okamoto Industries Inc., Pfizer Inc., Pregna International Ltd., Syncom Pharmaceuticals, Teva Pharmaceutical Industries Ltd., The Population Council, Veru Inc., Zydus Cadila, Shanghai Dahua Pharmaceutical Co. Ltd., Sichuan Kangdi Pharmaceutical Co. Ltd., Beijing Zhengyuan Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Chongqing Pharmaceutical Group Co. Ltd.

Contraceptive refers to a method or act that involves the use of a variety of medicines, sexual behaviours, chemicals, medications, or surgical procedures to intentionally prevent conception. Contraceptive is any method, measure, or action designed to keep a woman from getting pregnant.

The main product types of contraceptives include oral contraceptive pills, topical contraceptives, injectables, diaphragms, vaginal rings, condoms, contraceptive sponges, subdermal implants, and intra-uterine devices. Oral contraceptive pills are contraceptive tablets or birth control pills to prevent pregnancy. It includes hormones that prevent eggs from being released from the ovaries. The contraceptives are used by a wide range of age groups, ranging from 15-24 years, 25-34 years, 35-44 years, and over 44 years. The contraceptives are distributed by clinics, hospitals, independent pharmacies, and other locations.

The contraceptives market research report is one of a series of new reports that provides contraceptives market statistics, including contraceptives industry global market size, regional shares, competitors with a contraceptives market share, detailed contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the contraceptives industry. This contraceptives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

North America was the largest region in the contraceptives market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the contraceptives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The contraceptive market consists of sales of combined pills, Contraceptive patch, and female condoms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.